WHAT IS CLAIMED IS:

1. A compound of Formula (1) or a pharmaceutically acceptable salt thereof:



(1)

wherein:

$\mathbf{X_1}$ is CR_1 or N;

$\mathbf{X_2}$ is CR_2 or N;

$\mathbf{X_3}$ is CR_3 or N;

$\mathbf{X_4}$ is CR_4 or N;

each of $\mathbf{R_1}$, $\mathbf{R_2}$, $\mathbf{R_3}$, and $\mathbf{R_4}$ is independently selected from hydrogen, halogen, C_1-C_3alkoxy, and C_1-C_3haloalkyl, each of which is substituted with 0, 1, 2, or 3 R_S;

each $\mathbf{R_5}$ is independently selected from halogen, hydroxyl, C_1-C_3alkyl, C_1-C_3alkoxy, C_1-C_3haloalkyl, $-N(R_9)_2$, and -CN, each of which is substituted with 0, 1, 2, or 3 R_S;

each $\mathbf{R_6}$ is independently selected from hydrogen, halogen, C_1-C_3alkyl, and C_1-C_3haloalkyl, each of which is substituted with 0, 1, 2, or 3 R_S, or two $\mathbf{R_6}$ groups are taken together to form an oxo;

each $\mathbf{R_7}$ is independently selected from halogen, hydroxyl, C_1-C_3alkyl, C_1-C_3alkoxy, C_1-C_3haloalkyl, $-N(R_9)_2$, and -CN, each of which is substituted with 0, 1, 2, or 3 R_S;

each $\mathbf{R_8}$ is independently selected from hydrogen, hydroxyl, C_1-C_3alkyl, and C_1-C_3haloalkyl, each of which is substituted with 0, 1, 2, or 3 R_S, or two $\mathbf{R_8}$ groups are taken together to form an oxo;

each $\mathbf{R_9}$ is independently selected from hydrogen, C_1-C_3alkyl, -C(=O)(C_1-C_3alkyl), -C(=O)-O-(C_1-C_3alkyl), and -C(=O)-NH-(C_1-C_3alkyl), each of which is substituted with 0, 1, 2, or 3 R_S, or two $\mathbf{R_9}$ groups are taken together to form a 3- to 6-membered heterocycle or heteroaryl;

each $\mathbf{R_S}$ is independently selected from halogen, hydroxyl, C_1-C_3alkyl, C_1-C_3alkoxy, C_1-C_3haloalkyl, $-N(R_9)_2$, and -CN;

L is a linker of 1 to 16 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by C(O), O, $N(R_9)$, S, C_2-alkenyl, C_2-alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl, wherein the R_9, C_2-alkenyl, cycloalkyl, aryl, heterocycle, and heteroaryl are each independently substituted with 0, 1, 2, or 3 R_S;

m is 0, 1, or 2;

n is 0, 1, 2, or 3; and

o is 0, 1, 2, or 3,

wherein each hydrogen atom is independently and optionally replaced by a deuterium atom.

2. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein X_1 is N.

~~3. The compound or pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein X_2 is N.~~

~~4. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein X_1 and X_2 are each N.~~

~~5. The compound or pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein X_2 is CR_2, X_3 is CR_3, and X_4 is CR_4.~~

~~6. The compound or pharmaceutically acceptable salt thereof according to claim 5, wherein R_2, R_3, and R_4 are each independently selected from H and F.~~

~~7. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein X_1 is CR_1, X_2 is CR_2, X_3 is CR_3, and X_4 is CR_4.~~

~~8. The compound or pharmaceutically acceptable salt thereof according to claim 7, wherein R_1, R_2, R_3, and R_4 are each independently selected from H and F.~~

~~9. The compound or pharmaceutically acceptable salt thereof according to claim 7 or 8, wherein R_1 is F.~~

~~10. The compound or pharmaceutically acceptable salt thereof according to claim 7 or 8, wherein R_2 is F.~~

~~11. The compound or pharmaceutically acceptable salt thereof according to claim 7 or 8, wherein R_3 is F.~~

~~12. The compound or pharmaceutically acceptable salt thereof according to claim 7 or 8, wherein R_4 is F.~~

~~13. The compound or pharmaceutically acceptable salt thereof according to claim 7 or 8, wherein R_1 and R_3 are each F.~~

~~14. The compound or pharmaceutically acceptable salt thereof according to claim 7 or 8, wherein R_3 and R_4 are each F.~~

~~15. The compound or pharmaceutically acceptable salt thereof according to claim 9, wherein R_2, R_3, and R_4 are each H.~~

~~16. The compound or pharmaceutically acceptable salt thereof according to claim 10, wherein R_1, R_3, and R_4 are each H.~~

~~17. The compound or pharmaceutically acceptable salt thereof according to claim 11, wherein R_1, R_2, and R_4 are each H.~~

~~18. The compound or pharmaceutically acceptable salt thereof according to claim 12, wherein R_1, R_2, and R_3 are each H.~~

~~19. The compound or pharmaceutically acceptable salt thereof according to claim 13, wherein R_2 and R_4 are each H.~~

~~20. The compound or pharmaceutically acceptable salt thereof according to claim 14, wherein R_1 and R_2 are each H.~~

21. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein the  group is selected from , , , , , , , , and .

22. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 21, wherein each R_5 is independently selected from halogen, C_1-C_3alkoxy, and C_1-C_3haloalkyl.

23. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 22, wherein each R_5 is independently selected from -Cl, $-OCH_3$, and $-CF_3$.

24. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 23, wherein m is 0 or 1.

25. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 24, wherein m is 0.

26. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 25, wherein m is 1.

27. The compound or pharmaceutically acceptable salt according to any one of claims 1 to 26, wherein o is 0.

28. The compound or pharmaceutically acceptable salt according to any one of claims 1 to 26, wherein o is 1.

29. The compound or pharmaceutically acceptable salt according to any one of claims 1 to 23, wherein m and o are each 0.

30. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 29, wherein each R_6 is independently selected from H and C_1-C_3alkyl.

31. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 30, wherein each R_6 is independently selected from H and $-CH_3$.

32. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 31, wherein the two R_6 groups attached to the same carbon are identical.

33. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 31, wherein each R_6 is identical.

34. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 31, wherein each R_6 is different.

35. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 34, wherein the  group is selected from , , , , and .

36. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 34, wherein the group is selected from , , , , , , , and .

37. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 36, wherein each R_7 is independently selected from halogen, hydroxyl, C_1-C_3alkyl, and C_1-C_3haloalkyl.

38. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 37, wherein each R_7 is independently selected from halogen, hydroxyl, CH_3, and CF_3.

39. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 38, wherein each R_7 is independently selected from F, hydroxyl, CH_3, and CF_3.

40. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 39, wherein each R_7 is independently F.

41. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 37, wherein n is 0.

42. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 37, wherein n is 1.

43. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 42, wherein each R_8 is hydrogen or two R_8 groups are taken together to form an oxo.

44. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 42, wherein each R_8 is hydrogen.

45. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 42, wherein two R_8 groups are taken together to form an oxo.

46. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 45, wherein each R_9 is independently selected from hydrogen, C_1-C_3alkyl, and $C(=O)$-C_1-C_3alkyl.

47. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 46, wherein each R_9 is independently selected from hydrogen and C_1-C_3alkyl.

48. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 47, wherein each R_9 is independently selected from hydrogen, CH_3, CH_2CH_3, and $CH(CH_3)_2$.

49. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 36, wherein the  group is selected from  ,    ,    ,    , , and .

50. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 49, wherein L is a linker of 1 to 12 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by C(=O), O, N(R_9), S, C_2-alkenyl, C_2-alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl, wherein the R_9, C_2-alkenyl, cycloalkyl, aryl, heterocycle, and heteroaryl are each independently substituted with 0, 1, 2, or 3 R_S.

51. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 50, wherein L is a linker of 1 to 10 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by C(=O), O, N(R_9), S, C_2-alkenyl, C_2-alkynyl, cycloalkyl, aryl, heterocycle, or

heteroaryl, wherein the R_9, C_2-alkenyl, cycloalkyl, aryl, heterocycle, and heteroaryl are each independently substituted with 0, 1, 2, or 3 R_S.

52. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 51, wherein L is a linker of 1 to 8 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by C(=O), O, N(R_9), S, C_2-alkenyl, C_2-alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl, wherein the R_9, C_2-alkenyl, cycloalkyl, aryl, heterocycle, and heteroaryl are each independently substituted with 0, 1, 2, or 3 R_S.

53. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 52, wherein L is a linker of 1 to 6 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by C(=O), O, N(R_9), S, C_2-alkenyl, C_2-alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl, wherein the R_9, C_2-alkenyl, cycloalkyl, aryl, heterocycle, and heteroaryl are each independently substituted with 0, 1, 2, or 3 R_S.

54. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 53, wherein one or more carbon atoms of linker L are optionally replaced by C(=O), O, N(R_9), S, cycloalkyl, aryl, heterocycle, or heteroaryl, wherein the R_9, C_2-alkenyl, cycloalkyl, aryl, heterocycle, and heteroaryl are each independently substituted with 0, 1, 2, or 3 R_S.

55. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 54, wherein one or more carbon atoms of linker L are optionally replaced by O, N(R_9), cycloalkyl, or heterocycle, wherein the R_9, cycloalkyl, and heterocycle are each independently substituted with 0, 1, 2, or 3 R_S.

56. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 55, wherein at least one carbon atom of linker L is replaced by a heterocycle, which is substituted with 0, 1, 2, or 3 R_S.

57. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 55, wherein at least two carbon atoms of linker L are replaced by a heterocycle, each of which is substituted with 0, 1, 2, or 3 R_S.

58. The compound or pharmaceutically acceptable salt thereof according to claim 56 or 57, wherein the heterocycle is selected from piperidine and piperazine, each of which is substituted with 0, 1, 2, or 3 R_S.

59. The compound or pharmaceutically acceptable salt thereof according to claim 56 or 57, wherein the heterocycle is selected from  and .

60. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 49, wherein L is selected from: ,

.



, and .

~~61. The compound according to claim 1, wherein the compound is chosen from:~~

~~1~~	~~N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-((5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)oxy)benzamide;~~
~~2~~	~~N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)propoxy)propoxy)benzamide;~~
~~3~~	~~N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethoxy)benzamide~~
~~4~~	~~N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)propoxy)benzamide~~
~~5~~	~~N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)butoxy)benzamide~~
~~6~~	~~N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-((5-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)pentyl)oxy)benzamide~~
~~7~~	~~N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)nicotinamide~~
~~8~~	~~N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)(methyl)amino)butoxy)benzamide~~
~~9~~	~~N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)(methyl)amino)methyl)piperidin-1-yl)nicotinamide~~
~~10~~	~~N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)(ethyl)amino)methyl)piperidin-1-yl)nicotinamide~~

11	N ((1r,3r) 3 ((8 cyanoquinolin 5 yl)oxy) 2,2,4,4 tetramethylcyclobutyl) 6 (4 ((((1r,3r) 3 ((2 (2,6 dioxopiperidin 3 yl) 1,3 dioxoisoindolin 5 yl)oxy)cyclobutyl)(isopropyl)amino)methyl)piperidin 1 yl)nicotinamide
12	N ((1r,3r) 3 ((8 cyanoquinolin 5 yl)oxy) 2,2,4,4 tetramethylcyclobutyl) 6 (4 ((((1s,3s) 3 ((2 (2,6 dioxopiperidin 3 yl) 1,3 dioxoisoindolin 5 yl)oxy)cyclobutyl)(isopropyl)amino)methyl)piperidin 1 yl)nicotinamide
13	N ((1r,3r) 3 ((8 cyanoquinolin 5 yl)oxy) 2,2,4,4 tetramethylcyclobutyl) 6 (4 ((4 (2 (2,6 dioxopiperidin 3 yl) 1,3 dioxoisoindolin 5 yl)piperazin 1 yl)methyl)piperidin 1 yl)nicotinamide
14	N ((1S,3S) 3 ((8 cyanoquinolin 5 yl)oxy) 2,2 dimethylcyclobutyl) 6 (4 ((4 (2 (2,6 dioxopiperidin 3 yl) 1,3 dioxoisoindolin 5 yl)piperazin 1 yl)methyl)piperidin 1 yl)nicotinamide
15	N ((1r,3r) 3 ((8 cyanoquinolin 5 yl)oxy)cyclobutyl) 6 (4 ((4 (2 (2,6 dioxopiperidin 3 yl) 1,3 dioxoisoindolin 5 yl)piperazin 1 yl)methyl)piperidin 1 yl)nicotinamide
16	N ((1s,3s) 3 ((8 cyanoquinolin 5 yl)oxy)cyclobutyl) 6 (4 ((4 (2 (2,6 dioxopiperidin 3 yl) 1,3 dioxoisoindolin 5 yl)piperazin 1 yl)methyl)piperidin 1 yl)nicotinamide
17	N ((1S,3R) 3 ((8 cyanoquinolin 5 yl)oxy) 2,2 dimethylcyclobutyl) 6 (4 ((4 (2 (2,6 dioxopiperidin 3 yl) 1,3 dioxoisoindolin 5 yl)piperazin 1 yl)methyl)piperidin 1 yl)nicotinamide
18	N ((1r,3r) 3 ((8 cyanoquinolin 5 yl)oxy) 2,2,4,4 tetramethylcyclobutyl) 2 (4 ((4 (2 (2,6 dioxopiperidin 3 yl) 1,3 dioxoisoindolin 5 yl)piperazin 1 yl)methyl)piperidin 1 yl)pyrimidine 5 carboxamide
19	N ((1r,3r) 3 ((8 cyanoquinolin 5 yl)oxy) 2,2,4,4 tetramethylcyclobutyl) 6 (4 ((4 (2 (2,6 dioxopiperidin 3 yl) 1,3 dioxoisoindolin 5 yl)piperazin 1 yl)methyl)piperidin 1 yl)pyridazine 3 carboxamide
20	N ((1r,3r) 3 ((8 cyanoquinolin 5 yl)oxy) 2,2,4,4 tetramethylcyclobutyl) 5 (4 ((4 (2 (2,6 dioxopiperidin 3 yl) 1,3 dioxoisoindolin 5 yl)piperazin 1 yl)methyl)piperidin 1 yl)pyrazine 2 carboxamide
21	N ((1r,3r) 3 ((8 cyanoquinolin 5 yl)oxy) 2,2,4,4 tetramethylcyclobutyl) 4 (4 ((4 (2 (2,6 dioxopiperidin 3 yl) 1,3 dioxoisoindolin 5 yl)piperazin 1 yl)methyl)piperidin 1 yl)benzamide
22	N ((1r,3r) 3 ((8 cyanoquinolin 5 yl)oxy) 2,2,4,4 tetramethylcyclobutyl) 4 (4 ((4 (2 (2,6 dioxopiperidin 3 yl) 1,3 dioxoisoindolin 5 yl)piperazin 1 yl)methyl)piperidin 1 yl) 3 fluorobenzamide
23	N ((1r,3r) 3 ((8 cyanoquinolin 5 yl)oxy) 2,2,4,4 tetramethylcyclobutyl) 4 (4 (2 (4 (2 (2,6 dioxopiperidin 3 yl) 1,3 dioxoisoindolin 5 yl)piperazin 1 yl)ethyl)piperazin 1 yl) 3 fluorobenzamide
24	N ((1r,3r) 3 ((8 cyanoquinolin 5 yl)oxy) 2,2,4,4 tetramethylcyclobutyl) 4 (4 (2 (4 (2 (2,6 dioxopiperidin 3 yl) 1,3 dioxoisoindolin 5 yl)piperazin 1 yl)ethyl)piperidin 1 yl) 3 fluorobenzamide
25	N ((1r,3r) 3 ((8 cyanoquinolin 5 yl)oxy) 2,2,4,4 tetramethylcyclobutyl) 6 (4 (2 (4 (2 (2,6 dioxopiperidin 3 yl) 1,3 dioxoisoindolin 5 yl)piperazin 1 yl)ethyl)piperidin 1 yl)nicotinamide
26	N ((1r,3r) 3 ((8 cyanoquinolin 5 yl)oxy) 2,2,4,4 tetramethylcyclobutyl) 2 (4 (2 (4 (2 (2,6 dioxopiperidin 3 yl) 1,3 dioxoisoindolin 5 yl)piperazin 1 yl)ethyl)piperidin 1 yl)pyrimidine 5 carboxamide
27	N ((1r,3r) 3 ((8 cyanoquinolin 5 yl)oxy) 2,2,4,4 tetramethylcyclobutyl) 6 (4 (2 (4 (2 (2,6 dioxopiperidin 3 yl) 1,3 dioxoisoindolin 5 yl)piperazin 1 yl)ethyl)piperidin 1 yl)pyridazine 3 carboxamide
28	N ((1r,3r) 3 ((8 cyanoquinolin 5 yl)oxy) 2,2,4,4 tetramethylcyclobutyl) 6 (4 (2 (4 (2 (2,6 dioxopiperidin 3 yl) 1,3 dioxoisoindolin 5 yl)piperazin 1 yl)ethyl)piperidin 1 yl) 5 fluoronicotinamide
29	N ((1r,3r) 3 ((8 cyanoquinolin 5 yl)oxy) 2,2,4,4 tetramethylcyclobutyl) 6 (4 ((4 (2 ((S) 2,6 dioxopiperidin 3 yl) 1 oxoisoindolin 5 yl)piperazin 1 yl)methyl)piperidin 1 yl)nicotinamide

30	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrimidine-5-carboxamide
31	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide
32	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-3-fluorobenzamide
33	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)nicotinamide
34	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide
35	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide
36	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)nicotinamide
37	N-((1r,3S)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(((2S)-4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2-methylpiperazin-1-yl)methyl)piperidin-1-yl)nicotinamide
38	N-((1r,3R)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(((2R)-4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2-methylpiperazin-1-yl)methyl)piperidin-1-yl)nicotinamide
39	N-((1r,3S)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(((2S)-4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2-methylpiperazin-1-yl)methyl)piperidin-1-yl)benzamide
40	N-((1r,3R)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(((2R)-4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2-methylpiperazin-1-yl)methyl)piperidin-1-yl)benzamide
41	N-((1r,3R)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(((2R)-4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2-methylpiperazin-1-yl)methyl)piperidin-1-yl)benzamide
42	N-((1r,3R)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(((2R)-2-((dimethylamino)methyl)-4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-3-fluorobenzamide
43	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)benzamide
44	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)(isopropyl)amino)methyl)piperidin-1-yl)pyridazine-3-carboxamide
45	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(((2-(dimethylamino)ethyl)((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)amino)methyl)piperidin-1-yl)-3-fluorobenzamide
46	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-5-fluoronicotinamide
47	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide

48	N ((1r,3r) 3 ((8 cyanoquinolin 5 yl)oxy) 2,2,4,4 tetramethylcyclobutyl) 4 (4 ((4 (2 (2,6 dioxopiperidin 3 yl) 6 fluoro 1,3 dioxoisoindolin 5 yl)piperazin 1 yl)methyl)piperidin 1 yl) 3 fluorobenzamide
49	N ((1r,3r) 3 ((8 cyanoquinolin 5 yl)oxy) 2,2,4,4 tetramethylcyclobutyl) 4 (4 ((4 (2 ((S) 2,6 dioxopiperidin 3 yl) 1 oxoisoindolin 5 yl)piperazin 1 yl)methyl)piperidin 1 yl)benzamide
50	N ((1r,3r) 3 ((8 cyanoquinolin 5 yl)oxy) 2,2,4,4 tetramethylcyclobutyl) 2 (4 ((4 (2 (2,6 dioxopiperidin 3 yl) 6 fluoro 1,3 dioxoisoindolin 5 yl)piperazin 1 yl)methyl)piperidin 1 yl)pyrimidine 5 carboxamide
51	N ((1r,3r) 3 ((8 cyanoquinolin 5 yl)oxy) 2,2,4,4 tetramethylcyclobutyl) 4 (4 ((4 (2 (2,6 dioxopiperidin 3 yl) 1 oxoisoindolin 5 yl)piperazin 1 yl) methyl)piperidin 1 yl) 3 fluorobenzamide
52	N ((1r,3r) 3 ((8 cyanoquinolin 5 yl)oxy) 2,2,4,4 tetramethylcyclobutyl) 6 (4 ((4 (2 (2,6 dioxopiperidin 3 yl) 6 fluoro 1,3 dioxoisoindolin 5 yl)piperazin 1 yl)methyl)piperidin 1 yl) 5 fluoronicotinamide
53	N ((1r,3r) 3 ((8 cyanoquinolin 5 yl)oxy) 2,2,4,4 tetramethylcyclobutyl) 4 (4 ((4 (2 ((S) 2,6 dioxopiperidin 3 yl) 6 fluoro 1 oxoisoindolin 5 yl)piperazin 1 yl)methyl)piperidin 1 yl) 3 fluorobenzamide
54	N ((1r,3r) 3 ((8 cyanoquinolin 5 yl)oxy) 2,2,4,4 tetramethylcyclobutyl) 4 (4 ((((1r,3r) 3 ((2 (2,6 dioxopiperidin 3 yl) 1,3 dioxoisoindolin 5 yl)oxy)cyclobutyl)(ethyl)amino)methyl)piperidin 1 yl)benzamide

or a pharmaceutically acceptable salt thereof, wherein each hydrogen is independently and optionally replaced by a deuterium.

62. A pharmaceutical composition comprising at least one compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 61 and a pharmaceutically acceptable carrier.

63. The pharmaceutical composition according to claim 62, wherein the compound or pharmaceutically acceptable salt thereof is present in a therapeutically effective amount.

64. A method of treating cancer in a subject in need thereof, comprising administering to said subject a compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 61 or a pharmaceutical composition according to claim 62 or 63.

65. The method according to claim 64, wherein the cancer is selected from prostate cancer, head and neck cancer, skin cancer, sarcoma, renal cell carcinoma, adrenocortical carcinoma, bladder cancer, lung cancer, gastric carcinoma, esophageal carcinoma, pancreatic adenocarcinoma, colorectal cancer, connective tissue cancer, glioblastoma multiforme, cervical cancer, uterine cancer, ovarian cancer, and breast cancer.

66. The method according to claim 64 or 65, wherein the cancer is prostate cancer.

67. The method according to any one of claims 64 to 66, wherein the cancer is androgen receptor positive.

68. The method according to any one of claims 64 to 67, wherein the subject has been previously treated with an anti-cancer agent.

69. The method according to claim 68, wherein the anti-cancer agent is enzalutamide, apalutamide, bicalutamide, darolutamide, flutamide, abiraterone, or a combination of any of the foregoing.

70. The method according to claim 69, wherein the anti-cancer agent is enzalutamide.

~~71. A use of a compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 61 or a pharmaceutical composition according to claim 62 or 63 for treating cancer.~~

~~72. The use according to claim 71, wherein the cancer is selected from prostate cancer, head and neck cancer, skin cancer, sarcoma, renal cell carcinoma, adrenocortical carcinoma, bladder cancer, lung cancer, gastric carcinoma, esophageal carcinoma, pancreatic adenocarcinoma, colorectal cancer, connective tissue cancer, glioblastoma multiforme, cervical cancer, uterine cancer, ovarian cancer, and breast cancer.~~

~~73. The method according to claim 71 or 72, wherein the cancer is prostate cancer.~~

~~74. The method according to any one of claims 71 to 73, wherein the cancer is androgen receptor positive.~~

~~75. A use of a compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 61 or a pharmaceutical composition according to claim 62 or 63 in the manufacture of a medicament.~~

~~76. The use according to claim 75, wherein the medicament is for the treatment of a cancer selected from prostate cancer, head and neck cancer, skin cancer, sarcoma, renal cell carcinoma, adrenocortical carcinoma, bladder cancer, lung cancer, gastric carcinoma, esophageal carcinoma, pancreatic adenocarcinoma, colorectal cancer, connective tissue cancer, glioblastoma multiforme, cervical cancer, uterine cancer, ovarian cancer, and breast cancer.~~

~~77. The use according to claim 76, wherein the cancer is prostate cancer.~~

~~78. The use according to claim 76 or 77, wherein the cancer is androgen receptor positive.~~

~~79. A method of inhibiting cell growth, comprising contacting a cell with a compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 61 or a pharmaceutical composition according to claim 62 or 63.~~

~~80. The method according to claim 79, wherein the cell is a cancer cell.~~

~~81. The method according to claim 80, wherein the cancer cell is a prostate cancer cell.~~

~~82. The method according to any one of claims 79 to 81, wherein the cell is androgen receptor positive.~~

~~83. The compound of Formula (1) according to claim 1, wherein the compound is a compound of Formula (1A)~~



~~(1A).~~

1. A compound of Formula (1) or a pharmaceutically acceptable salt thereof:



(1)

wherein:

X_1 is CR_1 or N;

X_2 is CR_2 or N;

X_3 is CR_3 or N;

X_4 is CR_4 or N;

each of **R_1**, **R_2**, **R_3**, and **R_4** is independently selected from hydrogen, halogen, C_1-C_3alkoxy, and C_1-C_3haloalkyl, each of which is substituted with 0, 1, 2, or 3 R_S;

each **R_5** is independently selected from halogen, hydroxyl, C_1-C_3alkyl, C_1-C_3alkoxy, C_1-C_3haloalkyl, -$N(R_9)_2$, and -CN, each of which is substituted with 0, 1, 2, or 3 R_S;

each **R_6** is independently selected from hydrogen, halogen, C_1-C_3alkyl, and C_1-C_3haloalkyl, each of which is substituted with 0, 1, 2, or 3 R_S, or two **R_6** groups are taken together to form an oxo;

each **R_7** is independently selected from halogen, hydroxyl, C_1-C_3alkyl, C_1-C_3alkoxy, C_1-C_3haloalkyl, -$N(R_9)_2$, and -CN, each of which is substituted with 0, 1, 2, or 3 R_S;

each **R_8** is independently selected from hydrogen, hydroxyl, C_1-C_3alkyl, and C_1-C_3haloalkyl, each of which is substituted with 0, 1, 2, or 3 R_S, or two **R_8** groups are taken together to form an oxo;

each **R_9** is independently selected from hydrogen, C_1-C_3alkyl, -C(=O)-(C_1-C_3alkyl), -C(=O)-O-(C_1-C_3alkyl), and -C(=O)-NH-(C_1-C_3alkyl), each of which is substituted with 0, 1, 2, or 3 R_S, or two **R_9** groups are taken together to form a 3- to 6-membered heterocycle or heteroaryl;

each **R_S** is independently selected from halogen, hydroxyl, C_1-C_3alkyl, C_1-C_3alkoxy, C_1-C_3haloalkyl, -$N(R_9)_2$, and -CN;

L is a linker of 1 to 16 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by C(O), O, $N(R_9)$, S, C_2-alkenyl, C_2-alkynyl, cycloalkyl,

aryl, heterocycle, or heteroaryl, wherein the R_9, C_2-alkenyl, cycloalkyl, aryl, heterocycle, and heteroaryl are each independently substituted with 0, 1, 2, or 3 R_S;

m is 0, 1, or 2;

n is 0, 1, 2, or 3; and

o is 0, 1, 2, or 3,

wherein each hydrogen atom is independently and optionally replaced by a deuterium atom.

2. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein X_1 is N, wherein X_2 is N, or wherein X_1 and X_2 are each N.

3. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein X_2 is CR_2, X_3 is CR_3, and X_4 is CR_4, optionally wherein R_2, R_3, and R_4 are each independently selected from H and F.

4. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein X_1 is CR_1, X_2 is CR_2, X_3 is CR_3, and X_4 is CR_4, optionally wherein R_1, R_2, R_3, and R_4 are each independently selected from H and F.

5. The compound or pharmaceutically acceptable salt thereof according to any preceding claim, wherein the  group is selected from , , , , , , , , and .

6. The compound or pharmaceutically acceptable salt thereof according to any preceding claim, wherein each R_5 is independently selected from halogen, C_1-C_3alkoxy, and C_1-C_3haloalkyl, optionally wherein each R_5 is independently selected from -Cl, $-OCH_3$, and $-CF_3$.

7. The compound or pharmaceutically acceptable salt thereof according to any preceding claim, wherein m is 0 or 1.

8. The compound or pharmaceutically acceptable salt according to any preceding claim, wherein o is 0 or 1.

9. The compound or pharmaceutically acceptable salt thereof according to any preceding claim, wherein the  group is selected from , , , and , or from , , , , , , , and .

10. The compound or pharmaceutically acceptable salt thereof according to any preceding claim, wherein each R_7 is independently selected from halogen, hydroxyl, C_1-C_3alkyl, and C_1-C_3haloalkyl, optionally wherein each R_7 is independently selected from halogen, hydroxyl, -CH_3, and -CF_3.

11. The compound or pharmaceutically acceptable salt thereof according to any preceding claim, wherein n is 0 or 1.

12. The compound or pharmaceutically acceptable salt thereof according to any preceding claim, wherein each R_8 is hydrogen or two R_8 groups are taken together to form an oxo.

13. The compound or pharmaceutically acceptable salt thereof according to any preceding claim, wherein each R_9 is independently selected from hydrogen, C_1-C_3alkyl, and -C(=O)-C_1-C_3alkyl, optionally wherein each R_9 is independently selected from hydrogen and C_1-C_3alkyl, or wherein each R_9 is independently selected from hydrogen, -CH_3, -CH_2CH_3, and -$CH(CH_3)_2$.

14. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 9, wherein the  group is selected from , , , , , , , , , , , and .

15. The compound or pharmaceutically acceptable salt thereof according to any preceding claim, wherein L is a linker of 1 to 12 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by C(=O), O, N(R_9), S, C_2-alkenyl, C_2-alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl, wherein the R_9, C_2-alkenyl, cycloalkyl, aryl, heterocycle, and heteroaryl are each independently substituted with 0, 1, 2, or 3 R_S,

or wherein L is a linker of 1 to 10 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by C(=O), O, N(R_9), S, C_2-alkenyl, C_2-alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl, wherein the R_9, C_2-alkenyl, cycloalkyl, aryl, heterocycle, and heteroaryl are each independently substituted with 0, 1, 2, or 3 R_S,

or wherein L is a linker of 1 to 8 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by C(=O), O, N(R_9), S, C_2-alkenyl, C_2-alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl, wherein the R_9, C_2-alkenyl, cycloalkyl, aryl, heterocycle, and heteroaryl are each independently substituted with 0, 1, 2, or 3 R_S,

or wherein L is a linker of 1 to 6 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by C(=O), O, N(R_9), S, C_2-alkenyl, C_2-alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl, wherein the R_9, C_2-alkenyl, cycloalkyl, aryl, heterocycle, and heteroaryl are each independently substituted with 0, 1, 2, or 3 R_S.

16. The compound or pharmaceutically acceptable salt thereof according to any preceding claim, wherein one or more carbon atoms of linker L are optionally replaced by C(=O), O, N(R_9), S, cycloalkyl, aryl, heterocycle, or heteroaryl, wherein the R_9, C_2-alkenyl, cycloalkyl, aryl, heterocycle, and heteroaryl are each independently substituted with 0, 1, 2, or 3 R_S,

or wherein one or more carbon atoms of linker L are optionally replaced by O, N(R_9), cycloalkyl, or heterocycle, wherein the R_9, cycloalkyl, and heterocycle are each independently substituted with 0, 1, 2, or 3 R_S,

or wherein at least one carbon atom of linker L is replaced by a heterocycle, which is substituted with 0, 1, 2, or 3 R_S, optionally wherein the heterocycle is selected from piperidine and piperazine, each of which is substituted with 0, 1, 2, or 3 R_S,

or wherein at least two carbon atoms of linker L are replaced by a heterocycle, each of which is substituted with 0, 1, 2, or 3 R_S, optionally wherein the heterocycle is selected from piperidine and piperazine, each of which is substituted with 0, 1, 2, or 3 R_S.

17. The compound or pharmaceutically acceptable salt thereof according to any preceding claim, wherein L is selected from:









, , ,

, , ,

, , ,

, , , and

.

18. The compound according to claim 1, wherein the compound is chosen from:

1	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-((5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)oxy)benzamide;
2	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)propoxy)propoxy)benzamide;
3	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethoxy)benzamide
4	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)propoxy)benzamide
5	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)butoxy)benzamide

6	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-((5-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)pentyl)oxy)benzamide
7	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)nicotinamide
8	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)(methyl)amino)butoxy)benzamide
9	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)(methyl)amino)methyl)piperidin-1-yl)nicotinamide
10	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)(ethyl)amino)methyl)piperidin-1-yl)nicotinamide
11	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)(isopropyl)amino)methyl)piperidin-1-yl)nicotinamide
12	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((((1s,3s)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)(isopropyl)amino)methyl)piperidin-1-yl)nicotinamide
13	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)nicotinamide
14	N-((1S,3S)-3-((8-cyanoquinolin-5-yl)oxy)-2,2-dimethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)nicotinamide
15	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)cyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)nicotinamide
16	N-((1s,3s)-3-((8-cyanoquinolin-5-yl)oxy)cyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)nicotinamide

17	N-((1S,3R)-3-((8-cyanoquinolin-5-yl)oxy)-2,2-dimethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)nicotinamide
18	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrimidine-5-carboxamide
19	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide
20	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-5-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrazine-2-carboxamide
21	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide
22	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-3-fluorobenzamide
23	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperazin-1-yl)-3-fluorobenzamide
24	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)-3-fluorobenzamide
25	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)nicotinamide
26	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)pyrimidine-5-carboxamide
27	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)pyridazine-3-carboxamide

28	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)-5-fluoronicotinamide
29	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)nicotinamide
30	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrimidine-5-carboxamide
31	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide
32	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-3-fluorobenzamide
33	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)nicotinamide
34	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide
35	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide
36	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)nicotinamide
37	N-((1r,3S)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(((2S)-4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2-methylpiperazin-1-yl)methyl)piperidin-1-yl)nicotinamide
38	N-((1r,3R)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(((2R)-4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2-methylpiperazin-1-yl)methyl)piperidin-1-yl)nicotinamide

39	N-((1r,3S)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(((2S)-4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2-methylpiperazin-1-yl)methyl)piperidin-1-yl)benzamide
40	N-((1r,3R)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(((2R)-4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2-methylpiperazin-1-yl)methyl)piperidin-1-yl)benzamide
41	N-((1r,3R)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(((2R)-4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2-methylpiperazin-1-yl)methyl)piperidin-1-yl)benzamide
42	N-((1r,3R)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(((2R)-2-((dimethylamino)methyl)-4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-3-fluorobenzamide
43	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)benzamide
44	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)(isopropyl)amino)methyl)piperidin-1-yl)pyridazine-3-carboxamide
45	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(((2-(dimethylamino)ethyl)((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)amino)methyl)piperidin-1-yl)-3-fluorobenzamide
46	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-5-fluoronicotinamide
47	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide
48	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-3-fluorobenzamide

49	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide
50	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrimidine-5-carboxamide
51	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl) methyl)piperidin-1-yl)-3-fluorobenzamide
52	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-5-fluoronicotinamide
53	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-3-fluorobenzamide
54	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)(ethyl)amino)methyl)piperidin-1-yl)benzamide

or a pharmaceutically acceptable salt thereof, wherein each hydrogen is independently and optionally replaced by a deuterium.

19. A pharmaceutical composition comprising at least one compound or pharmaceutically acceptable salt thereof according to any preceding claim and a pharmaceutically acceptable carrier, optionally wherein the compound or pharmaceutically acceptable salt thereof is present in a therapeutically effective amount.

20. Use of a compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 18 or a pharmaceutical composition according to claim 19 in the manufacture of a medicament for the treatment of cancer.

21. The use according to claim 20, wherein the cancer is selected from prostate cancer, head and neck cancer, skin cancer, sarcoma, renal cell carcinoma, adrenocortical carcinoma, bladder cancer, lung cancer, gastric carcinoma, esophageal carcinoma, pancreatic adenocarcinoma, colorectal cancer, connective tissue cancer,

glioblastoma multiforme, cervical cancer, uterine cancer, ovarian cancer, and breast canceroptionally wherein the cancer is prostate cancer, or wherein the cancer is androgen receptor positive.

22. The compound of Formula (1) according to claim 1, wherein the compound is a compound of Formula (1A)



(1A).

23. A compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 18 or a pharmaceutical composition according to claim 19 for use in therapy.